Clinical Trial Update: Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of nivolumab, ipilimumab, and cabozantinib in patients with unresectable advanced melanoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• cabozantinib (cabozantinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Georgetown University | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-11-27